Alsaab HO, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. https://doi.org/10.3389/fphar.2017.00561

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armand P, Shipp MA, Ribrag V et al (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733–3739. https://doi.org/10.1200/JCO.2016.67.3467

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moskowitz AJ, Shah G, Schöder H et al (2021) Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 39(28):3109–3117. https://doi.org/10.1200/JCO.21.01056

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bryan LJ, Smith SE, Allen P et al (2019) Safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment. Blood 134(Supplement_1):4029. https://doi.org/10.1182/blood-2019-123879

Article  Google Scholar 

Herrera AF, LeBlanc M, Castellino SM et al (2024) Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma. N Engl J Med 391(15):1379–1389. https://doi.org/10.1056/NEJMoa2405888

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Feng Y, Bajaj G et al (2017) Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacomet Syst Pharmacol 6(1):40–48. https://doi.org/10.1002/psp4.12133

Article  CAS  Google Scholar 

Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7

Article  CAS  PubMed  Google Scholar 

Stroh M, Winter H, Marchand M et al (2017) Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther 102(2):305–312. https://doi.org/10.1002/cpt.587

Article  CAS  PubMed  Google Scholar 

Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Journal of Clinical Oncology. https://ascopubs.org/doi/full/10.1200/JCO.2009.26.7609. Accessed 11 Jan 2025

Patil VM, Noronha V, Joshi A et al (2019) Low doses in immunotherapy: are they effective? Cancer Res Statistics, and Treatment 2(1):54. https://doi.org/10.4103/CRST.CRST_29_19

Article  Google Scholar 

Lepik KV, Fedorova LV, Kondakova EV et al (2020) A phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed/refractory Hodgkin lymphoma. Hemasphere 4(5):e480. https://doi.org/10.1097/HS9.0000000000000480

Article  PubMed  PubMed Central  Google Scholar 

Chan TSY, Hwang YY, Khong PL et al (2020) Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource-constrained setting. Hematol Oncol 38(5):726–736. https://doi.org/10.1002/hon.2787

Article  CAS  PubMed  Google Scholar 

Fedorova L, Lepik K, Mikhailova N et al (2022) P062: the efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma. Hemasphere 6(Suppl):28–29. https://doi.org/10.1097/01.HS9.0000890816.89900.95

Article  PubMed Central  Google Scholar 

Colunga-Pedraza PR, Vaquera-Alfaro HA, Guzmán-Martínez Z et al (2024) Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma. Ann Hematol 103(12):5607–5614. https://doi.org/10.1007/s00277-024-06098-9

Article  CAS  PubMed  Google Scholar 

Kwong YL, Lopes D, Khong PL (2017) Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. Br J Haematol 176(1):131–132. https://doi.org/10.1111/bjh.13920

Article  CAS  PubMed  Google Scholar 

Minson A, Douglas G, Bilmon I, Grigg A (2019) Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD. Br J Haematol 184(5):840–844. https://doi.org/10.1111/bjh.15186

Article  PubMed  Google Scholar 

Hwang YY, Khong PL, Kwong YL (2017) Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol 96(7):1219–1220. https://doi.org/10.1007/s00277-017-3007-9

Article  PubMed  Google Scholar 

Onizuka M, Kojima M, Matsui K et al (2017) Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol 106(1):141–145. https://doi.org/10.1007/s12185-017-2181-9

Article  CAS  PubMed  Google Scholar 

4. Systematic reviews of effectiveness - JBI Manual for Evidence Synthesis - JBI Global Wiki. https://jbi-global-wiki.refined.site/space/MANUAL/355827955/4.+Systematic+reviews+of+effectiveness. Accessed 10 Jan 2025

Pathak N, Pramanik R, Bakhshi S et al (2022) Modified protocol of nivolumab in relapsed/refractory Hodgkin lymphoma: a brief communication of real world data. J Immunother 45(5):239. https://doi.org/10.1097/CJI.0000000000000411

Article  CAS  PubMed  Google Scholar 

Lepik KV, Kozlov AV, Borzenkova E et al (2018) Safety and efficacy of nivolumab applied at different dosage in the patients with relapsing Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation. Cell Ther Transplant 7:28–35

Google Scholar 

Villasboas JC, Ansell SM, Witzig TE (2016) Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 7(11):13260–13264. https://doi.org/10.18632/oncotarget.7177

Article  PubMed  PubMed Central  Google Scholar 

Hur JY, Yoon SE, Kim SJ, Kim WS (2020) Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study. Blood Research 55(2):85–90. https://doi.org/10.5045/br.2020.2020014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL (2017) Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol 96(4):647–651. https://doi.org/10.1007/s00277-017-2931-z

Article  CAS  PubMed  Google Scholar 

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification | Journal of Clinical Oncology. https://ascopubs.org/doi/10.1200/JCO.2013.54.8800. Accessed 26 June 2025

Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489–2496. https://doi.org/10.1182/blood-2016-05-718528

Article  CAS  PubMed  Google Scholar 

Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50(8):1257–1260. https://doi.org/10.1080/10428190903040048

Article  PubMed  Google Scholar 

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study | Blood Advances | American Society of Hematology. https://ashpublications.org/bloodadvances/article/7/20/6266/497222/Nivolumab-for-relapsed-refractory-classical. Accessed 24 Jan 2025

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma | Blood | American Society of Hematology. https://ashpublications.org/blood/article/142/10/878/496370/Five-year-follow-up-of-KEYNOTE-087-pembrolizumab. Accessed 24 Jan 2025

Herbaux C, Gauthier J, Brice P et al (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471–2478. https://doi.org/10.1182/blood-2016-11-749556

Article  CAS  PubMed  Google Scholar 

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72. https://doi.org/10.1186/s40425-016-0177-2

Article